Cardiac replacement with a total artificial heart as a bridge to transplantation. Summary of the clinical use of the Symbion total artificial heart: a registry report. Johnson KE, Prieto M, Joyce LD, Pritzker M, Emery RW. Left ventricular device implantation for advanced cardiac amyloidosis. Swiecicki PL, Edwards BS, Kushwaha SS, Dispenzieri A, Park SJ, Gerts MA. The role of the total artificial heart in the treatment of post-myocardial infarction ventricular septal defect. Percutaneous ventricular assist device support in a patient with a Postinfarction Ventricular Septal Defect. Gregoric ID, Bieniarz MC, Arora H, Frazier OH, Kar B, Loyalka P. Post-infarction ventricular septal defect: surgical outcomes in the last decade. Ventricular assist device support in children and adolescents with heart ailure: the Children’s Medical Center Dallas Experience. Total artificial heart in the pediatric patient with biventricular heart failure. Park SS, Sanders DB, Smith BP, Ryan J, Plasencia J, Osborn MB, et al. CardioWest total artificial heart in a moribund adolescent with left ventricular thrombi. Smith MC, Arabia FA, Tsau PH, Smith RG, Bose RK, Woolley DS, Rhenman BE, Sthi GK, Copeland JG. Implantation of total artificial heart in congenital heart disease. Morales LS, Khan MS, Gottlieb, Krishnamurthy R, Dreyer WJ, Adachi I. The Cardio West artificial heart for chronic heart transplant rejection. Yoda M, El-banayosy A, Tendrich G, Koerfer R, Minami K. Role of the total artificial heart in the management of heart transplant rejection and retransplantation: case report and review. Kalya A, Jaroszewski D, Pajaro O, Scott R, Gopalan R, Kasper D, Arabia F. Changes in the functional status measures of heart failure patients with MCS. Leibner ES, Cysyk J, Eleuteri K, El-Banayosy A, Boehmer JP, Pae WE. INTERMACS profiles of advanced heart failure: the current picture. Stevenson LW, Pagani FD, Young JB, Jessup M, Miller L, Kormos RL, Naftel DC, et al. Fifth INTERMACS annual report: risk factor analysis from more than 6,000 mechanical circulatory support patients. Right ventricular failure with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. Kormos RL, Teuteberg JJ, Pagani FD, et al. Mechanical circulatory support for right heart failure: current technology and future outlook. Hsu PL, Parker J, Egger C, Autschbach R, Schmitz-Rode T, Steinseifer U. Orthotopic heart transplant versus left ventricular assist device: a national comparison of cost and survival. Mulloy DP, Bhamidipati CM, Stone ML, et al. ![]() Mechanical circulatory support: devices, outcomes and complications. State-of-the-art implantable cardiac assist device therapy for heart failure: bridge to transplant and destination therapy. Initial experience with the AbioCor implantable replacement heart system. ![]() 1982 28:534–8.ĭowling RD, Gray LA, Etoch SW, Laks H, Marelli D, Samuels L, Couper G, Vlahakes GJ, Frazier OH. Total Artificial Heart (TAH) utilization in man. Washington, DC: National Academy Press 1991.įrazier OH, Akutsu T, Cooley DA. The artificial heart: prototypes, policies and patients. Its main use has been as a bridge to transplant for those critically ill, and in desperate need of a donor heart. Over 1600 patients have been implanted with 16 different total artificial hearts. He survived 112 days but succumbed to strokes. The first long-term TAH implanted was the Jarvik-7 that was implanted in 1982 in Barney Clark a dentist, who had been diagnosed with terminal heart failure and was not a heart transplant candidate. The next implantation of a TAH was delayed until 1981 when the Akutsu III was implanted also at the Texas Heart Institute. The first use of an artificial heart in a human took place in 1969 with the implantation of the Liotta TAH, which sustained the life of a patient for 64 h prior to a heart transplant. Congress established the National Advisory Council to recommend the long-range research required for the development of a total artificial heart. Although the concept of developing a pump to propel blood appears simple, the development of the total artificial heart has rivaled the most important scientific projects of mankind. The development of the total artificial heart (TAH) for replacement of the failing human heart has attracted the spirit of humanity and the best minds in medical sciences, engineering, and ethics.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |